What is included in this Sample?
- * Market Segmentation
- * Key Findings
- * Research Scope
- * Table of Content
- * Report Structure
- * Report Methodology
Download FREE Sample Report
Avascular Necrosis Market Size, Share, Growth, and Industry Analysis, By Type (Trauma Related Avascular Necrosis (AVN) & Non-Trauma Related Avascular Necrosis (AVN)), By End-users (Hospitals, Clinics, Diagnostic Centers, & Ambulatory Surgical Centers), and Regional Insights and Forecast to 2034
Trending Insights

Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities

Our Research is the Cornerstone of 1000 Firms to Stay in the Lead

1000 Top Companies Partner with Us to Explore Fresh Revenue Channels
AVASCULAR NECROSIS MARKET OVERVIEW
The global Avascular Necrosis market size was USD 0.73 billion in 2025 and is projected to touch USD 1.54 billion in 2034, exhibiting a CAGR of 8.63% during the forecast period.
The Avascular Necrosis (AVN) Market is the treatment and diagnosis of a condition due to withdrawal of blood supply to bones and following death of bone, causing collapse of joints. Increased awareness, enhanced imaging technology, and increasing abuse of steroids and trauma are fueling the market. The market consists of pharmaceuticals, surgical therapy, and regenerative therapy like stem cell therapy. An increase in healthcare spending and R&D investments is also responsible for growth in this market. Acceptability in the North American market is driving the overall AVN market across the world, followed by Europe and Asia-Pacific. The Avascular Necrosis (AVN) Market was severely affected during pandemic years with a steep decline due to the COVID-19 pandemic.
COVID-19 IMPACT
Avascular Necrosis Industry Had a Negative Effect Due to service disruptions during COVID-19 Pandemic
The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.
Ever since the redeployment of health care services to treat the cases of COVID-19, elective surgeries and non-emergency operations for the cases of AVN were suspended or ceased. Diagnosis levels were kept low and treatment was postponed, and hence the growth in the market was curbed. With disrupted supply chains and fewer patient visits, also therapy and equipment for the case of AVN were not utilized. Overall, the pandemic decelerated the market's pace in the short term and impacted new product development processes. The Avascular Necrosis (AVN) market is witnessing some important trends, of which regenerative medicine, or stem cell–based therapy, is at the center of paradigm shifts in managing the disease.
LATEST TRENDS
Regenerative Therapies Drive Market Growth with Promising Treatment Alternatives
There is a general movement towards greater utilization of personalized medicine with the potential to deliver directed treatment based on clinical and genetic biomarkers, high-definition MRI/CT scanning to identify earlier, and more extensive use of minimally invasive surgical procedures such as arthroscopy and core decompression. In all of these trends, the most significant one is unregulated growth and clinical application of regenerative modalities like mesenchymal stem cell therapy, PRP, and tissue-engineered scaffolds capable of regenerating necrotic bone, revascularizing tissues, and weaning the dependency on joint-replacement surgery. It is a follow-up to Regrow Biosciences' OSSGROW, a customized bone cell therapy on Phase II FDA trials with stem cells derived from autologous bone marrow regrowing osteoblasts and potentially changing the treatment trajectory of AVN. On this premise, regenerative medicine increasingly offers a promising alternative to conventional surgeries with guarantees of bone regrowth with quick recuperation and improved prognosis.
AVASCULAR NECROSIS MARKET SEGMENTATION
By Type
Based on Type, the global market can be categorized into Trauma Related Avascular Necrosis (AVN) & Non-Trauma Related Avascular Necrosis (AVN)
- Trauma Related Avascular Necrosis (AVN): Physical trauma of joint dislocation or fracture that leads to disruption of the blood supply to the bone causes trauma-related AVN. High incidences of sports accidents and injuries make this category have the highest market share in the AVN market. Core decompression or replacement of the joint is used very commonly in treatment. Imaging technology and awareness are fuelling early diagnosis and market growth in this category.
- Non-Trauma Related Avascular Necrosis (AVN): Non-trauma-associated AVN is disease-related as a result of long-term steroid use, alcoholism, or illnesses such as sickle cell disease and lupus. This segment is expanding with the expansion of lifestyle diseases as well as long-term drug abuse. Pharmacologic management and regenerative medicine are the hot favourites of this segment. Enhanced screening and preventive treatment are driving growth in this segment in the AVN market.
By End-Users
Based on End-users, the global market can be categorized into Hospitals, Clinics, Diagnostic Centers, & Ambulatory Surgical Centers
- Hospitals: Hospitals are one of the largest end users of the Avascular Necrosis (AVN) Market, as they weave a large infrastructure and well-equipped theatres. They get a huge quantity of AVN cases, primarily those involving complex procedures such as bone grafts or joint replacements. Easy accessibility by multidisciplinary teams allows precise diagnosis, post-operative care, and treatment. Medical costs increase, and patients' tendency towards market players having well-equipped facilities increases the hospital segment growth.
- Clinics: Clinics also play a role in cases of early diagnosis and non-surgical management of AVN. The first consultation, pain management, and follow-ups of low-grade cases are treated in clinics. Affordable and easily accessible clinics make them the first point of contact for outpatients. Rising awareness and the establishment of specialty orthopaedics clinics are fuelling the segment's growth.
- Diagnostic Centres: Diagnostic centres are also making their mark in the AVN market by offering cutting-edge imaging investigations such as MRI and CT scans for early identification of bone injury. They are essential in the proper and timely diagnosis of AVN, facilitating optimal treatment planning. Development of technology in the application of diagnostic technology is improving efficiency and eliminating delay in treatment. Technological progress in the field is being driven by increased need for early diagnosis.
- Ambulatory Surgical Centres (ASCs): ASCs conduct minimally invasive AVN surgery, e.g., core decompression, on an outpatient basis. They provide cost-effective options to hospital-based procedures with shorter recovery periods. Efficiency and patient satisfaction orientation of their processes is making them more popular for conducting AVN procedures. An increase in the number of ASCs available and innovation in technology are driving growth in this segment of the market.
MARKET DYNAMICS
Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.
Driving Factors
Rising Health Conditions Fuel Market Growth and Treatment Demand
Rising prevalence of conditions such as alcoholism, obesity, and long-term corticosteroid therapy is driving the Avascular Necrosis (AVN) market considerably. All the diseases are causing damage in the blood supply to bone, thus subjecting patients to AVN development. Sickle cell anaemia and lupus are also chronic diseases that have contributed to a rise in patients. With the global medical conditions rising day by day, so is demand for AVN diagnosis and treatment.
Regenerative Imaging Advances Accelerate Market Growth and Treatment Options
Breakthrough advances in diagnostic imaging technology, including high-resolution CT scanning and MRI, and platelet-rich plasma (PRP) treatment are transforming AVN treatment. Surgery is increasingly being challenged by less invasive regenerative treatments as well as improved vessel reconstitution and bone repair. Likewise, advances in imaging technology in the advent of high-resolution CT scanning and MRI enable early diagnosis, leading to maximum effectiveness with treatment. All these developments are expanding the treatments and propelling growth in the AVN market.
Restraining Factor
High Treatment Costs Limit Market Growth Despite Medical Advances
One of the main drawbacks of the Avascular Necrosis (AVN) Market is the expense of newer forms of therapy such as surgery and regenerative medicine. Replacement of joints, stem cell therapy, and rehabilitation over decades are typically beyond the economic means of most patients, particularly in underdeveloped nations. Inadequate insurance coverage for new and investigational treatments also discourages their widespread use. Aside from this, poor infrastructure and qualified staff in rural or backward areas impede prompt diagnosis and treatment. Delayed diagnosis due to poor awareness yields substandard outcomes at added expense. Such cost and access obstacles limit the market growth despite advances in medicine.

Regenerative Therapies and Awareness Drive Strong Market Growth
Opportunity
The most desirable opportunities for the Avascular Necrosis Market Growth are heightened applications of regenerative therapy, such as stem-cell and gene-based therapies. These new technologies enable actual bone growth, more than the radical surgery, just like a joint replacement. With successful clinical trials, patients and increasing numbers of doctors are willing to try these treatments. Governments as well as the private entities are investing in R&D and encouraging healthcare infrastructure.
Enhanced consciousness and early diagnosis equipment are pushing the potential of patients who can be cured by these medicines. Apart from this, the growing number of elderly in other countries and high incidences of chronic diseases are driving demand. All these factors together provide a very strong base for the Avascular Necrosis Market to experience enormous growth in the coming next few years.

Limited Early Diagnosis Hinders Market Growth and Treatment Access
Challenge
Avascular Necrosis Market is in its early stage and is nonspecific; hence, diagnosis is complex. The initial and primary symptom is arthropathy of the general joint, which is the central factor in impacting patients and most commonly becomes involved in other musculoskeletal diseases and results in delayed or inappropriate treatment. If not treated at the early stage, the disease becomes contagious, causing bone fracture in case of an accident during surgery.
Delayed diagnosis of this type hinders the efficiency of management by non-surgical means in the form of medication and regeneration therapy. Further, in most regions, it’s not possible to utilize costly imaging facilities like MRI, or they are not even available, therefore serving as a hindrance to diagnosis. Patient and primary care physician unawareness is one of the causes of the issue.
-
Request a Free sample to learn more about this report
AVASCULAR NECROSIS MARKET REGIONAL INSIGHTS
-
North America
North America’s Innovation and Spending Drive Market Growth Leadership
The market leader in the Avascular Necrosis is North America because it possesses well-established healthcare centres, early uptake of the latest technology-based innovative therapies, and an increased level of awareness. It is supported by substantial R&D spending and the existence of leading pharma and biotech companies. The United States Avascular Necrosis Market is large because of huge health spending and the availability of innovative therapy like stem cell therapy in the country. The U.S. leads in licensed and under clinical research AVN drugs and therapies. Overall, healthcare and technological availability in North America put the region on par with that of the world's Avascular Necrosis market.
-
Europe
Europe’s Advanced Healthcare Fuels Market Growth and Innovation Leadership
Europe holds a significant portion in the global Avascular Necrosis Market Share mostly because of the highly developed healthcare infrastructure in the region as well as the research priority given to orthopaedic therapy. The use of the new diagnostic kit and regenerative medicines to treat early cases of AVN on the continent is promising as well. New clinical procedures and new approaches to treatment are pioneered by Germany, France, and the UK. Good policy and medicine spending are growth drivers in this market, as on the continent.
-
Asia
Asia’s Market Growth Driven by Demand, Investment, Initiatives
Asia is dominating the Avascular Necrosis Market because of an increasing patient population, increased health awareness, and improved medical infrastructure. India, China, and Japan are exhibiting more cases with higher steroid abuse rates, alcoholism, and trauma cases. Increased orthopaedic centres and investments in low-cost treatment processes are driving local market growth. Additionally, government initiatives and medical tourism are driving Asia as a significant contributor to the overall AVN market.
KEY INDUSTRY PLAYERS
Market Growth Driven by Innovation, Technology, And R&D Collaboration
The key market leaders are reshaping the Avascular Necrosis (AVN) market increasingly by driving innovation in creating new alternatives, expanding therapy choices, and enhancing results in patients. Drug and biotechnology firms are making investments in regenerative medicine, i.e., gene- and cell therapy-based therapies, to provide pain-free alternatives to replacement orthopaedic surgery. Mass-market competitors are adopting the newest image-based technology, which will make early detection and intervention better. Other than this, market competitors are also collaborating with research firms in order to conduct clinical trials and thereby support the discovery of new therapy. Greater focus on R&D and alliances will propel the market development and improve AVN patient recovery.
List Of Top Avascular Necrosis Companies
- Ethicon (U.S.)
- Wright Medical (U.S.)
- Bayer (Germany)
- Merck (U.S.)
- Aurobindo Pharma (India)
KEY INDUSTRY DEVELOPMENT
March 2024: Yale School of Medicine researchers have achieved a breakthrough in avascular necrosis (AVN) treatment with the introduction of less invasive surgery supported by 3D pre-surgical modelling and computer assistance. The new procedure targets exact core decompression of the femoral head to prevent complications and joint collapse (in patients with early AVN). With the help of synergy between surgical navigation and imaging in orthopedics, minimally invasive technique gives a less traumatic and site-specific approach to surgery compared to conventional methods, and this is a major advancement in the management of AVN.
REPORT COVERAGE
The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.
This research report examines the segmentation of the market by using both quantitative and qualitative methods to provide a thorough analysis that also evaluates the influence of strategic and financial perspectives on the market. Additionally, the report's regional assessments consider the dominant supply and demand forces that impact market growth. The competitive landscape is detailed meticulously, including shares of significant market competitors. The report incorporates unconventional research techniques, methodologies and key strategies tailored for the anticipated frame of time. Overall, it offers valuable and comprehensive insights into the market dynamics professionally and understandably.
Attributes | Details |
---|---|
Market Size Value In |
US$ 0.73 Billion in 2025 |
Market Size Value By |
US$ 1.54 Billion by 2034 |
Growth Rate |
CAGR of 8.63% from 2025 to 2034 |
Forecast Period |
2025-2034 |
Base Year |
2024 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
|
By Type
|
|
By Application
|
FAQs
The global Avascular Necrosis market is expected to reach USD 1.54 billion in 2034.
The Avascular Necrosis market is expected to exhibit a CAGR of 8.63% by 2034.
Increasing Incidence of Lifestyle and Chronic Health Conditions & Advancements in Regenerative Medicine and Imaging Technologies to expand the market growth.
The key market segmentation, which includes, based on type, the Avascular Necrosis market is Trauma Related Avascular Necrosis (AVN) & Non-Trauma Related Avascular Necrosis (AVN). Based on End-users, the Avascular Necrosis market is classified as Hospitals, Clinics, Diagnostic Centers, & Ambulatory Surgical Centers.